Yuting Bian 1 , Toru Yamashita 1 , Yuki Taira 1 , Jingwei Shang 1 , Keiichiro Tsunoda 1 , Tian Feng 1 , Ryo Sasaki 1 , Xia Liu 1 , Xiaowen Shi 1 , Koh Tadokoro 1 , Emi Nomura 1 , Namiko Matsumoto 1 , Yusuke Osakada 1 , Yoshio Omote 1 , Mami Takemoto 1 , Nozomi Hishikawa 1 , Yasuyuki Ohta 1 , Koji Abe 1 Show Affiliations »
Abstract
BACKGROUND: Cerebral ischemia causes a strong inflammatory response. Neumentix is a dietary supplement containing 14.9% rosmarinic acid and 29.9% total phenolic content, which has been proved to be beneficial against inflammatory response. Therefore, Neumentix's effect on anti-inflammatory and blood brain barrier (BBB) disruption in transient middle cerebral artery occlusion (tMCAO) model mice is investigated in this study. METHODS: After the pretreatment of vehicle or Neumentix 134 mg/kg/d, intraperitoneal injection (i.p.) (containing rosmarinic acid 20 mg/kg/d) for 14 days, mice were subjected to tMCAO for 60 min and kept receiving vehicle or Neumentix daily 5 days afterward. RESULTS: Neumentix treatment ameliorated neurobehavioral impairment in the corner test (5d after tMCAO, **P<0.01), reduced infarct volume (#P<0.05), suppressed expression of ionized calciumbinding adapter molecule-1 (Iba-1), tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) (###P<0.001), and improved the integrity of BBB (§P<0.05) at 5 days after tMCAO. CONCLUSION: The present study provided an evidence of Neumentix's anti-inflammatory and neuroprotection effect against BBB disruption on experimental tMCAO model mice, suggesting that Neumentix could be a potential therapeutic agent for stroke. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
BACKGROUND: Cerebral ischemia causes a strong inflammatory response. Neumentix is a dietary supplement containing 14.9% rosmarinic acid and 29.9% total phenolic content, which has been proved to be beneficial against inflammatory response. Therefore, Neumentix's effect on anti-inflammatory and blood brain barrier (BBB) disruption in transient middle cerebral artery occlusion (tMCAO ) model mice is investigated in this study. METHODS: After the pretreatment of vehicle or Neumentix 134 mg/kg/d, intraperitoneal injection (i.p.) (containing rosmarinic acid 20 mg/kg/d) for 14 days, mice were subjected to tMCAO for 60 min and kept receiving vehicle or Neumentix daily 5 days afterward. RESULTS: Neumentix treatment ameliorated neurobehavioral impairment in the corner test (5d after tMCAO , **P<0.01), reduced infarct volume (#P<0.05), suppressed expression of ionized calciumbinding adapter molecule-1 (Iba-1 ), tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1 ) (###P<0.001), and improved the integrity of BBB (§P<0.05) at 5 days after tMCAO . CONCLUSION: The present study provided an evidence of Neumentix's anti-inflammatory and neuroprotection effect against BBB disruption on experimental tMCAO model mice , suggesting that Neumentix could be a potential therapeutic agent for stroke . Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Entities: Chemical
Disease
Gene
Species
Keywords:
Ischemic stroke; anti-inflammation; bloodzzm321990brain barrier; middle cerebral artery occlusion; polyphenolic complex; rosmarinic acid
Year: 2020
PMID： 32416676 DOI： 10.2174/1567202617666200517105727
Source DB: PubMed Journal: Curr Neurovasc Res ISSN： 1567-2026 Impact factor: 1.990